Compugen Ltd. announced on July 28, 2025, that it will present a pooled analysis of data from three Phase 1 trials evaluating COM701 at ESMO 2025, scheduled for October 17-21, 2025, in Berlin, Germany. The presentation will focus on COM701 as monotherapy and combination therapy in heavily pretreated platinum-resistant ovarian cancer patients.
The poster presentation, titled 'COM701 in Ovarian Cancer: A Pooled Analysis of 3 Phase 1 Clinical Trials,' will be delivered by Dr. Oladapo Yeku from Massachusetts General Hospital. This presentation aims to provide a comprehensive overview of COM701's anti-tumor activity and safety profile from its earlier clinical development.
This presentation at a prominent international oncology conference offers an opportunity to further highlight the potential of COM701 to the global scientific and medical community. The data is expected to inform the ongoing development strategy for COM701, particularly its evaluation in the maintenance setting for platinum-sensitive ovarian cancer.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.